For the first time ever, U.S. News & World Report has released ratings of telehealth platforms offering GLP-1 weight-loss drugs.
The inaugural ratings evaluated 20 online platforms that offer FDA-approved, brand-name GLP-1 medications, such as semaglutide (Wegovy), tirzepatide (Zepbound), and orforglipron (Foundayo).
Overall, 11 of the platforms received top ratings, including Amazon One Medical, Noom, Ro, and WeightWatchers.
Companies that only offer compounded GLP-1 medications — which are not FDA-approved and may carry greater risks — were not included in the ratings. However, some telehealth platforms included in the ratings may provide compounded medications, U.S. News noted.
The company pointed to growing demand for GLP-1 medications as the reason for rolling out the new resource, adding that patients have to navigate complicated fee structures, varying levels of physician oversight, and complex insurance processes when trying to find a good telehealth provider.
“As millions of Americans look online to access these treatments, they’re facing a crowded, confusing landscape filled with hidden costs and varying levels of clinical care and oversight,” Gretel Schueller, managing editor of health at U.S. News, said in a statement. “Our debut ratings were designed to cut through that noise so they can find a trustworthy telehealth provider of GLP-1s.”
Schueller noted that a U.S. News survey from earlier this year revealed that 52% of health experts said GLP-1 expansion would be the “single biggest public health trend of 2026.”
She added that telehealth platforms should “serve as a tool to support” patient care, rather than being a replacement for in-person care, urging patients to “look for platforms offering real-time interaction with a licensed healthcare provider, and to always keep their primary care physician in the loop to align GLP-1 treatment with their long-term health goals.”
Schueller also said in the statement that each telehealth platform caters to specific needs. For instance, Amazon One Medical has dedicated insurance support, Found has thorough medical oversight, Noom has comprehensive lifestyle and nutrition coaching, and Ro has the best customer satisfaction.
She noted 85% of respondents to user feedback surveys rated their experience with their telehealth platform as “very good” or “excellent,” and nearly two-thirds lost more than 10% of their body weight. When people “choose a telehealth platform grounded in high clinical standards,” Schueller said, using telehealth to get GLP-1s can be “an effective and safe way to lose weight.”
To determine the ratings, U.S. News evaluated platforms on a 5-point scale across 6 categories — including clinical support, health screening processes, transparency, insurance support, supplemental support, and customer satisfaction — as well as feedback from more than 1,200 active GLP-1 telehealth users.
The 11 top performing GLP-1 telehealth platforms were as follows:
- Amazon One Medical
- Found
- Fridays
- Ivim Health
- LifeMD
- Mochi Health
- Noom
- PlushCare
- Remedy Meds
- Ro
- WeightWatchers
